1800 Total Publications
Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration.
Leung, K. K., Bartlett, J. W., Barnes, J., Manning, E. N., Ourselin, S., & Fox, N. C.
2013; Journal Neurology; vol. 80; no. 7; pp. 648-54;
AWUVIqi8dzjauPDbjhrM
doi:10.1212/WNL.0b013e318281ccd3
Disease progression model in subjects with mild cognitive impairment from the Alzheimer’s disease neuroimaging initiative: CSF biomarkers predict population subtypes.
Samtani, M. N., Raghavan, N., Shi, Y., Novak, G., Farnum, M., Lobanov, V., … Narayan, V. a.
2013; Journal British Journal of Clinical Pharmacology; vol. 75; no. 1; pp. 146-161;
AWUU_d3HdzjauPDbjhqf
doi:10.1111/j.1365-2125.2012.04308.x
Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people.
Wirth, M., Villeneuve, S., Haase, C. M., Madison, C. M., Oh, H., Landau, S. M., … Jagust, W. J.
2013; Journal JAMA Neurology; vol. 70; no. 12; pp. 1512-9;
AWUVIqi8dzjauPDbjhrC
doi:10.1001/jamaneurol.2013.4013
Comparison of Imaging Biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging
Whitwell, J. L., Wiste, H. J., Weigand, S. D., Rocca, W. A., Knopman, D. S., Roberts, R. O., … Jack, C. R.
PMID: 22782510
;
PMCID:3569033
; 2012; Journal JAMA Neurology; vol. 69; no. 5; pp. 614-22;
AWTX9JHXwAl_G9zjEvXu
doi:10.1001/archneurol.2011.3029